Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Parathyroid Disease Treatment Market Size Forecast: How Big Could The Market Get By 2030?
The parathyroid disease treatment market size has demonstrated robust growth in recent years. It is projected to increase from $2.37 billion in 2025 to $2.54 billion in 2026, at a compound annual growth rate (CAGR) of 7.2%. The historical growth of this market can be attributed to factors such as the rising prevalence of hyperparathyroidism, limited awareness of parathyroid disorders, a dependence on conventional hormone replacement therapy, a lack of advanced surgical interventions, and constrained hospital pharmacy infrastructure.
The parathyroid disease treatment market is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $3.31 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.8%. The expansion over the forecast period can be attributed to several factors, including the rising demand for calcimimetics and bisphosphonates, enhancements in parathyroid imaging and diagnostics, the development of homecare and telemedicine options, regulatory backing for precision medicine, and the proliferation of specialty centers focusing on endocrine disorders. Key trends projected for this period encompass a greater uptake of calcimimetics and bisphosphonates, an increasing preference for parenteral administration over oral methods in severe conditions, an expansion of hospital and specialized care environments, an intensified focus on customized hormone replacement therapies, and the incorporation of lifestyle and nutritional strategies into treatment protocols.
Get A Free Sample Report With In-Depth Market Insights:
Parathyroid Disease Treatment Market Growth Momentum: What Factors Are Shaping Demand?
The increasing occurrence of chronic kidney disease (CKD) is anticipated to drive expansion in the parathyroid disease treatment market in the future. CKD represents a prolonged ailment characterized by the progressive decline of kidney function, resulting in mineral imbalances, particularly concerning calcium and phosphorus. The growing prevalence of chronic kidney disease (CKD) stems primarily from the rising incidence of diabetes, given that consistently elevated blood sugar levels can progressively harm the kidney’s filtering structures, culminating in diabetic nephropathy. Treatment for parathyroid disease plays a crucial role in the management of chronic kidney disease (CKD) through its focus on secondary hyperparathyroidism, which is a common complication in advanced CKD, causing disturbances in calcium and phosphorus equilibrium, fostering bone disease, and encouraging vascular calcification. For example, as reported in May 2024 by the Centers for Disease Control and Prevention (CDC), a US-based government public health agency, an estimated 35.5 million people, or roughly 14% of adults in the US (more than one in seven), were affected by chronic kidney disease in 2023, with nearly 90% of these individuals unaware of their condition. Consequently, the increasing prevalence of chronic kidney disease is propelling the expansion of the parathyroid disease treatment market.
Parathyroid Disease Treatment Market Segments: Where Is Growth Concentrated?
The parathyroid disease treatment market covered in this report is segmented –
1) By Treatment: Calcimimetics, Bisphosphonates, Plicamycin, Hormone Replacement Therapy, Other Treatments
2) By Route Of Administration: Oral, Parenteral
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users
Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Bisphosphonates: Alendronate, Ibandronate, Risedronate, Zoledronic Acid
3) By Plicamycin: Mithramycin (Plicamycin) Monotherapy, Combination Therapies Involving Plicamycin
4) By Hormone Replacement Therapy: Estrogen Therapy, Progesterone Therapy, Combined Hormonal Therapies, Selective Estrogen Receptor Modulators (SERMs)
5) By Other Treatments: Parathyroid Hormone (PTH) Analogues, Surgery (Parathyroidectomy), Dietary Supplements, Lifestyle And Nutritional Interventions
Parathyroid Disease Treatment Market Trends Redefining Industry Growth
Major companies operating in the parathyroid disease treatment market are concentrating on developing innovative products, such as parathyroid hormone prodrugs, to improve calcium regulation and lessen dosing frequency for patients with hypoparathyroidism. Parathyroid hormone (PTH) prodrugs are inactive compounds that convert into active PTH within the body to balance calcium and phosphate levels. For instance, in August 2024, Ascendis Pharma A/S, a Denmark-based biopharmaceutical company, gained US Food and Drug Administration (FDA) approval for YORVIPATH (palopegteriparatide), a prodrug of parathyroid hormone (PTH[1-34]) for treating chronic hypoparathyroidism in adults. This once-daily therapy offers continuous parathyroid hormone exposure over 24 hours, serving as an alternative to typical calcium and vitamin D supplementation by directly addressing the underlying hormone deficiency. The approval of YORVIPATH emphasizes the rising importance of advanced hormone replacement therapies focused on improving treatment adherence and providing enhanced clinical outcomes for individuals with parathyroid disorders.
Parathyroid Disease Treatment Market Key Participants And Competitive Landscape
Major companies operating in the parathyroid disease treatment market are AstraZeneca PLC, Amgen Inc., Kyowa Kirin Co. Ltd., OPKO Health Inc., Septerna Inc., Entera Bio Ltd., Visen Pharmaceuticals (Shanghai) Co. Ltd., Ascendis Pharma A/S, Aeterna Zentaris Inc., MBX Biosciences Inc., Crinetics Pharmaceuticals Inc., Vidasym Inc., Rani Therapeutics LLC, Pathalys Pharma Inc.
View The Full Parathyroid Disease Treatment Market Report:
Parathyroid Disease Treatment Market Geographic Analysis: Where Is Demand Rising Fastest?
Asia-Pacific was the largest region in the parathyroid disease treatment market in 2025. The regions covered in the parathyroid disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
